Galina A. Proshchai, Sergey V. Dudarenko, Alexander S. Partcerniak, Elena Yu. Zagarskikh, Sergey A. Partcerniak
Objective: To evaluate the possibility of using fibroblast growth factor 21 (FGF 21) as a marker of metabolic disorders and premature aging in polymorbid cardiovascular pathology. Research methods: 199 men aged 35–55 years who were stratified into 3 groups were examined: group A – 117 patients with type 2 diabetes mellitus (type 2 diabetes), polymorbid cardiovascular disease (PCVD), obesity, androgen deficiency and anxiety-depressive disorders (ADD); group B – 55 patients with PCVD, obesity and ADD; group C – control group (n = 27). The examination of patients included a laboratory study of the level of FGF 21, indicators of carbohydrate and lipid metabolism, hormonal status, as well as daily monitoring of blood pressure and ECG. Results and conclusions. When compared with the control group, the level of FGF 21 was 3 times higher in the presence of type 2 diabetes. The most intense increase in FGF 21 levels was observed in groups of patients with several diseases. An increase in the level of FGF 21 in young and middle-aged people is probably due to a compensatory reaction to the existing androgen deficiency, disorders of carbohydrate and lipid metabolism. Strong correlations between FGF 21 and glucose, HDL cholesterol, total testosterone, ALT, and SBP during the day allow FGF 21 to be considered an early marker of cardiovascular disease and premature aging (PA) in young and middle-aged people.
keywords: sfibroblast growth factor 21, diabetes mellitus, obesity, polymorbid cardiovascular pathology, premature aging

for references: Galina A. Proshchai, Sergey V. Dudarenko, Alexander S. Partcerniak, Elena Yu. Zagarskikh, Sergey A. Partcerniak. Fibroblast growth factor 21 from the perspective of a promising marker of metabolic disorders and premature aging in polymorbid cardiovascular pathology in young and middle-aged people. Neotlozhnaya kardiologiya i kardioovaskulyarnye riski [Emergency cardiology and cardiovascular risks], 2020, vol. 4, no. 2, pp. 1002–1005

1. Plakuev A.N., Yuryeva M. Yu., Yuriev Yu.Yu. Sovremenny’e koncepcii stareniya i ocenka biologicheskogo vozrasta cheloveka [Modern concepts of aging and estimation of the biological age of a person]. Human Ecology, 2011, no. 4, pp. 17-25. (in Russian).
2. Bryantseva O.V., Proshchaev K.I. Medizinskie aspecty prezhdevremennogo stareniya: sovremennoe sostoyanie problemy [Medical aspects of premature ageing: modern condition of the problem]. Nauchny’e vedomosti BelGU. Ser. Medicina. Farmaciya, 2011, no. 4 (99), pp. 23-27. (in Russian).
3. Pristrom M.S., Pristrom S.L., Semenenkov I.I. Starenie phyziologicheskoe I prezh-devremennoe. Sovremennyy vzglyad na problemy [Physiological and early aging. Modern view of the problem]. Med news, 2015, no. 2, pp. 36-44. (in Russian).
4. Berglund E.D., Li C.Y., Bina H.A., Lynes S.E., Michael M.D., Shanafelt A.B., Kharitonenkov A., Wasserman D.H. Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology, 2009, vol. 150, no. 9, pp. 4084-4093. doi: 10.1210/en.2009-0221.
5. Lin Z., Tian H., Lam K.S., Lin S., Hoo R.C., Konishi M., Itoh N., Wang Y., Bornstein S.R, Xu A., Li X. Adiponectin mediates the metabolic effects of FGF 21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab, 2013, vol. 17, no. 5, pp. 779-789. doi: 10.1016/j.cmet.2013.04.005.
6. Parcerniak A.S., Aflitonov M.A., Khalimof Y.Sh., Parcerniak S.A., Topanova A.A., Proshai G.A. Vzaisvaz urovnja factora rosta fibroblastov 21 b lipoproteinov u muzchin molodogo I srednego vozrasta s polimorbidnoj serdechno-sosudistoj patologiej [The relationship between the level of fibroblast 21 growth factor and lipoproteins in young and middle-aged men with polymorbid cardiovascular disease]. Arterial’naya gipertenziya, 2015, vol. 21, no. 5, pp. 493-499. (in Russian).
7. Kuznik B.I., Khavinson V. Kh., Linkova N.S., Ry’jak G.A., Sall’ T.S., Trofimova S.V. Factory rosta fibroblastov FGF19, FGF 21, FGF23 kak endocrinnye regulyatory phyziologicheskich phuncziy i geroprotectory. Epigeneticheskie mechanizmy regulyazii [Growth factors of fibroblasts FGF19, FGF21, FGF23 as endocrine regula-tors of physiological functions and geroprotectors. Epigenetic regulatory mechanisms]. Uspehi sovrem biologii, 2017, vol. 137, no. 1, pp. 84-99. (in Russian).
8. An S.Y., Lee M.S., Yi S.A., Ha E.S., Han S.J., Kim H.J., Kim D.J., Lee K.W. Serum fibroblast growth factor 21 was elevated in subjects with type 2 diabetes mellitus and was associated- with the presence of carotid artery plaques. Diabetes Research and Clinical Practice, 2012, vol. 96, no. 2, pp. 196-203. doi: 10.1016/j.diabres.2012.01.004.
9. Lin Z., Wu Z., Yin X., Liu Y., Yan X., Lin S., Xiao J., Wang X., Feng W., Li X. Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLoS ONE, 2010, vol. 5, no. 12, p. e15534. doi: 10.1371/journal.pone.0015534.
10. Zagarskikh E.Yu., Proshchai G.A., Vorokhobina N.V. Factor rosta fibroblastov-21 kak marker prezdevremennogo stareniya u muzhchin molodogo i srednego vozrasta [Fibroblast growth factor 21 as a marker of premature aging in young and middled-aged men with type 2 diabetes]. Urologiia, 2018, no. 1, pp. 92-95. (in Russian).
11. Kurnikova A.A., Shukshina L.M., Shukshin D.V. Vozrastnoy androgennyy deficit u bol’nych sacharnym diabetom 2 tipa, vzaimosvyaz’ s serdecho-sosudistymi zabolevaniyami [Age-related androgen deficiency in patients with type 2 diabetes, the relationship with cardiovascular diseases]. Evraz kardiol Jurn, 2016, no. 3, pp. 73. (in Russian).
12. Santos R.L. Silva F.B., Ribeiro R.F., Stefanon I. Sex hormones in the cardiovascular system. Horm Mol Biol Clin Investig, 2014, vol. 18, no. 2, pp. 89-103. doi: 10.1515/hmbci-2013-0048.
File extension: pdf (251.82 KB)